EP1755584A4 - Treatment of myopia - Google Patents

Treatment of myopia

Info

Publication number
EP1755584A4
EP1755584A4 EP05746596A EP05746596A EP1755584A4 EP 1755584 A4 EP1755584 A4 EP 1755584A4 EP 05746596 A EP05746596 A EP 05746596A EP 05746596 A EP05746596 A EP 05746596A EP 1755584 A4 EP1755584 A4 EP 1755584A4
Authority
EP
European Patent Office
Prior art keywords
myopia
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05746596A
Other languages
German (de)
French (fr)
Other versions
EP1755584A1 (en
Inventor
Daniel M Schwartz
Chang Jun Yu
Robert H Grubbs
Julia A Kornfield
Scott E Fraser
Matthew S Mattson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
California Institute of Technology CalTech
University of California
Original Assignee
California Institute of Technology CalTech
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Institute of Technology CalTech, University of California filed Critical California Institute of Technology CalTech
Publication of EP1755584A1 publication Critical patent/EP1755584A1/en
Publication of EP1755584A4 publication Critical patent/EP1755584A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP05746596A 2004-05-07 2005-05-09 Treatment of myopia Withdrawn EP1755584A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56913704P 2004-05-07 2004-05-07
PCT/US2005/016072 WO2005110397A1 (en) 2004-05-07 2005-05-09 Treatment of myopia

Publications (2)

Publication Number Publication Date
EP1755584A1 EP1755584A1 (en) 2007-02-28
EP1755584A4 true EP1755584A4 (en) 2007-10-31

Family

ID=35393980

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05746596A Withdrawn EP1755584A4 (en) 2004-05-07 2005-05-09 Treatment of myopia

Country Status (6)

Country Link
US (1) US7727544B2 (en)
EP (1) EP1755584A4 (en)
JP (1) JP2007536272A (en)
KR (1) KR20070011557A (en)
CN (1) CN1980651A (en)
WO (1) WO2005110397A1 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8965487B2 (en) * 2004-08-24 2015-02-24 The General Hospital Corporation Process, system and software arrangement for measuring a mechanical strain and elastic properties of a sample
DE102005056958A1 (en) * 2005-11-29 2007-06-06 Rowiak Gmbh Method and device for machining a workpiece
GB2435211B (en) 2006-01-25 2009-08-26 Alan Whitmore Drug delivery system
EP1854438B1 (en) * 2006-05-09 2018-07-04 IROC Services AG Ophthalmologic device for preventing myopia
US7535991B2 (en) 2006-10-16 2009-05-19 Oraya Therapeutics, Inc. Portable orthovoltage radiotherapy
US7620147B2 (en) 2006-12-13 2009-11-17 Oraya Therapeutics, Inc. Orthovoltage radiotherapy
JP5559540B2 (en) * 2006-10-24 2014-07-23 カリフォルニア・インスティテュート・オブ・テクノロジー Photochemotherapy to affect the mechanical and / or chemical properties of body tissues
US10278947B2 (en) 2007-02-28 2019-05-07 Orthopeutics, L.P. Crosslinker enhanced repair of connective tissues
US8580789B2 (en) * 2007-04-02 2013-11-12 The Cleveland Clinic Foundation Treating glaucoma
US8363783B2 (en) 2007-06-04 2013-01-29 Oraya Therapeutics, Inc. Method and device for ocular alignment and coupling of ocular structures
WO2008148517A1 (en) * 2007-06-04 2008-12-11 Carl Zeiss Meditec Ag Method for determining the power of an intraocular lens
US8506558B2 (en) 2008-01-11 2013-08-13 Oraya Therapeutics, Inc. System and method for performing an ocular irradiation procedure
WO2009073213A1 (en) 2007-12-05 2009-06-11 Avedro, Inc. Eye therapy system
EP3272395B1 (en) 2007-12-23 2019-07-17 Carl Zeiss Meditec, Inc. Devices for detecting, controlling, and predicting radiation delivery
US7801271B2 (en) 2007-12-23 2010-09-21 Oraya Therapeutics, Inc. Methods and devices for orthovoltage ocular radiotherapy and treatment planning
WO2010039854A1 (en) 2008-09-30 2010-04-08 Neal Marshall Eye therapy system
US8883214B2 (en) * 2009-01-13 2014-11-11 The Regents Of The University Of California Implantable delivery vehicle for ocular delivery of muscarinic antagonists
US8574277B2 (en) 2009-10-21 2013-11-05 Avedro Inc. Eye therapy
EP3556330A1 (en) * 2010-03-19 2019-10-23 Avedro, Inc. Systems for applying and monitoring eye therapy
EP2552406B1 (en) * 2010-03-26 2018-01-24 Stemmatters, Biotecnologia e Medicina Regenerativa, S.A. Photo-crosslinked gellan gum-based hydrogels: preparation methods and uses thereof
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
WO2012112543A2 (en) * 2011-02-15 2012-08-23 Seros Medical, Llc Method and apparatus for the delivery of photo-chemical (cross-linking) treatment to scleral tissue
US20120310141A1 (en) * 2011-05-06 2012-12-06 Kornfield Julia A Light delivery device and related compositions, methods and systems
WO2012162529A1 (en) 2011-05-24 2012-11-29 Avedro, Inc. Systems and methods for reshaping an eye feature
EP2713849B1 (en) 2011-06-02 2017-02-15 Avedro, Inc. Systems for monitoring time based photo active agent delivery or photo active marker presence
US20120330291A1 (en) * 2011-06-24 2012-12-27 The Regents Of The University Of California Nonlinear optical photodynamic therapy (nlo-pdt) of the cornea
WO2013148895A1 (en) 2012-03-29 2013-10-03 Cxl Ophthalmics, Llc Ocular cross-linking system and method for sealing corneal wounds
EP2830637A4 (en) 2012-03-29 2016-03-16 Cxl Ophthalmics Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
WO2013148896A1 (en) 2012-03-29 2013-10-03 Cxl Ophthalmics, Llc Ocular treatment solutions, delivery devices and delivery augmentation methods
US20150119792A1 (en) * 2012-05-08 2015-04-30 The Regents Of The University Of California Light degradable drug delivery system for ocular therapy
EP4074294A1 (en) 2012-07-16 2022-10-19 Avedro, Inc. Systems and methods for corneal cross-linking with pulsed light
EP2922919B1 (en) 2012-11-21 2020-03-25 University Of Louisville Research Foundation, Inc. Compositions and methods for reducing oxidative damage
WO2014145666A2 (en) * 2013-03-15 2014-09-18 Avedro, Inc. Treatments of extracellular matrices of the eye
US9498114B2 (en) 2013-06-18 2016-11-22 Avedro, Inc. Systems and methods for determining biomechanical properties of the eye for applying treatment
WO2014205145A1 (en) 2013-06-18 2014-12-24 Avedro, Inc. Systems and methods for determining biomechanical properties of the eye for applying treatment
CN107205845B (en) 2014-10-27 2020-03-31 艾维德洛公司 Systems and methods for cross-linking treatment of the eye
US10114205B2 (en) 2014-11-13 2018-10-30 Avedro, Inc. Multipass virtually imaged phased array etalon
WO2016130478A1 (en) 2015-02-09 2016-08-18 University Of Louisville Research Foundation, Inc. Ophthalmic compositions and methods for reducing oxidative damage to an eye lens
EP3285704B1 (en) 2015-04-24 2020-11-18 Avedro Inc. Systems for photoactivating a photosensitizer applied to an eye
CN107849265A (en) * 2015-05-14 2018-03-27 加州理工学院 Use upper conversion nano particle and the light accommodating intraocular lens of near-infrared (NIR) light
EP3297589A4 (en) 2015-05-22 2019-03-06 Avedro Inc. Systems and methods for monitoring cross-linking activity for corneal treatments
KR20180030892A (en) 2015-07-21 2018-03-26 아베드로 인코퍼레이티드 System and method for treating eye with photosensitizer
EP3383329A4 (en) 2015-12-03 2019-08-07 Avedro, Inc. Systems and methods for treating an eye with a mask device
US10765777B2 (en) 2017-06-28 2020-09-08 California Institute Of Technology Light adjustable intraocular lenses using upconverting core-shell nanoparticles and near infrared (NIR) light
CN108371713B (en) * 2018-02-11 2020-03-31 重庆医科大学 Pullulan drug delivery system induced and crosslinked by visible light and preparation method thereof
CN108057122B (en) * 2018-02-11 2020-03-31 重庆医科大学 Adriamycin-loaded natural pullulan polysaccharide drug-loading system and preparation method thereof
EP3761928A1 (en) 2018-03-08 2021-01-13 Avedro, Inc. Micro-devices for treatment of an eye
US11702546B2 (en) 2018-10-24 2023-07-18 California Institute Of Technology Near-infrared heptamethine dyes for generation of singlet oxygen
JP2022503941A (en) * 2018-10-24 2022-01-12 カリフォルニア インスティチュート オブ テクノロジー Treatment of myopia and other eye conditions with singlet oxygen produced from dyes activated by near-infrared irradiation
US11298263B2 (en) 2019-07-16 2022-04-12 Jack T. Holladay Method of mitigating myopia development and related instrumentation
AU2020326998A1 (en) 2019-08-06 2022-03-24 Avedro, Inc. Photoactivation systems and methods for corneal cross-linking treatments
CN116617586B (en) * 2023-05-25 2024-01-23 北京工业大学 Light control system for ultraviolet crosslinking auxiliary infrared light irradiation, application and method

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352310A (en) * 1989-02-17 1994-10-04 Natter Marc D Actinic activation shaping system and method
WO1997031033A1 (en) * 1996-02-22 1997-08-28 Dsm N.V. Anionic photocatalyst
EP0995421A2 (en) * 1998-10-23 2000-04-26 Heraeus Kulzer GmbH & Co.KG Light polymerisable single-component dental material
WO2001087560A1 (en) * 2000-05-15 2001-11-22 HYDRO-QUéBEC Permanent decrease of wood hardness
WO2002012350A2 (en) * 2000-08-04 2002-02-14 Lintfield Limited Photoinitiated reactions
WO2004004757A1 (en) * 2002-07-02 2004-01-15 The Regents Of The University Of California Treatment for eye disorder

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3891278T1 (en) * 1988-03-25 1990-03-15 Vitebskij Tech I Legkoj Promy EXPLANATE FOR THE SURGICAL FASTENING OF THE DEFORMED SQUERA OF THE EYE APPLE
US5626863A (en) 1992-02-28 1997-05-06 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US20030087985A1 (en) 1990-10-15 2003-05-08 Hubbell Jeffrey A. Gels for encapsulation of biological materials
US5462990A (en) 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5468505A (en) 1992-02-28 1995-11-21 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
US5573934A (en) 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
DK0627911T3 (en) 1992-02-28 2000-11-20 Univ Texas Photopolymerizable biodegradable hydrogels as tissue contact materials and controlled release carriers
US20040138329A1 (en) 1992-04-20 2004-07-15 Board Of Regents Of The University Of Texas System Gels for encapsulation of biological materials
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
US5800373A (en) 1995-03-23 1998-09-01 Focal, Inc. Initiator priming for improved adherence of gels to substrates
US5458505A (en) * 1994-02-03 1995-10-17 Prager; Jay H. Lamp cooling system
US5798349A (en) 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
US5935942A (en) 1994-12-14 1999-08-10 Zeimer; Ran Selective and non-invasive visualization or treatment of vasculature
JP4209941B2 (en) 1995-03-23 2009-01-14 ジェンザイム・コーポレーション Undercoat redox and photoinitiator systems for improved adhesion of gels to substrates
US6461640B1 (en) 1995-12-08 2002-10-08 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
US5756541A (en) 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US6059828A (en) 1996-03-18 2000-05-09 Peyman; Gholam A. Macular indentor for use in the treatment of subretinal neovascular membranes
BR9811793A (en) 1997-07-18 2000-09-26 Infimed Inc Biodegradable macromers for the controlled release of biologically active substances.
US6128525A (en) 1997-07-29 2000-10-03 Zeng; Haishan Apparatus and method to monitor photodynamic therapy (PDT)
JP2001520979A (en) 1997-10-27 2001-11-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Methods and pharmaceutical compositions for retinal wound closure
US6858229B1 (en) 1999-04-26 2005-02-22 California Institute Of Technology In situ forming hydrogels
US6271233B1 (en) 1999-08-10 2001-08-07 Ciba Vision Corporation Method for treating ocular neovascular diseases
US6267954B1 (en) 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US7291673B2 (en) 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
WO2003086305A2 (en) * 2002-04-10 2003-10-23 The Regents Of The University Of California Biodegradable peg-based polymer formulations in ocular applications
EP1713440A4 (en) * 2004-01-23 2009-10-28 California Inst Of Techn Engineered proteins, and methods of making and using

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352310A (en) * 1989-02-17 1994-10-04 Natter Marc D Actinic activation shaping system and method
WO1997031033A1 (en) * 1996-02-22 1997-08-28 Dsm N.V. Anionic photocatalyst
EP0995421A2 (en) * 1998-10-23 2000-04-26 Heraeus Kulzer GmbH & Co.KG Light polymerisable single-component dental material
WO2001087560A1 (en) * 2000-05-15 2001-11-22 HYDRO-QUéBEC Permanent decrease of wood hardness
WO2002012350A2 (en) * 2000-08-04 2002-02-14 Lintfield Limited Photoinitiated reactions
WO2004004757A1 (en) * 2002-07-02 2004-01-15 The Regents Of The University Of California Treatment for eye disorder

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANANDA M SARKER ET AL: "Tetraorganylborate salts as convenient precursors for photogeneration of tertiary amines", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 2, CHEMICAL SOCIETY. LETCHWORTH, GB, no. 10, 1998, pages 2315 - 2322, XP008080549, ISSN: 1472-779X *
See also references of WO2005110397A1 *
WOLLENSAK GREGOR ET AL: "Collagen crosslinking of human and porcine sclera.", JOURNAL OF CATARACT AND REFRACTIVE SURGERY MAR 2004, vol. 30, no. 3, March 2004 (2004-03-01), pages 689 - 695, XP002450030, ISSN: 0886-3350 *

Also Published As

Publication number Publication date
CN1980651A (en) 2007-06-13
US7727544B2 (en) 2010-06-01
EP1755584A1 (en) 2007-02-28
JP2007536272A (en) 2007-12-13
US20050271590A1 (en) 2005-12-08
WO2005110397A1 (en) 2005-11-24
KR20070011557A (en) 2007-01-24

Similar Documents

Publication Publication Date Title
EP1755584A4 (en) Treatment of myopia
EG24420A (en) Treatment of ophthalmic conditions
EP1742675A4 (en) Treatment of biomedical waste
EP1838714A4 (en) Methods of treating pain
IL178996A0 (en) Thienopyridinone compounds and methods of treatment
IL182436A0 (en) Thienopyridinone compounds and methods of treatment
GB0404656D0 (en) Treatment of spinal conditions
IL182993A0 (en) Treatment of mastitis
GB2430002B (en) Well treatment
ZA200610736B (en) Treatment of hydrocarbons
EP1793813A4 (en) Treatment of adhd
GB0426196D0 (en) Methods of treatment
GB0410502D0 (en) Treatment of metakaolin
GB0701549D0 (en) Skin treatment
GB0424085D0 (en) Well treatment
GB0425854D0 (en) Therapeutic treatment
GB0625234D0 (en) Treatment of Hydrocarbons
GB0423173D0 (en) Treatment of diabetes
ZA200704046B (en) Treatment of burns
HU0400952D0 (en) Treatment of anus-cancer
GB0422012D0 (en) Methods of treatment
GB0408752D0 (en) Therapeutic treatment
GB0407710D0 (en) Treatment of diseases
GB0412416D0 (en) Treatment of incontinence
GB0418556D0 (en) The treatment of pain

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061110

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: YU, CHANG, JUN

Inventor name: GRUBBS, ROBERT, H.

Inventor name: MATTSON, MATTHEW S.

Inventor name: KORNFIELD, JULIA, A.

Inventor name: FRASER, SCOTT, E.

Inventor name: SCHWARTZ, DANIEL, M.

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 33/04 20060101ALI20070919BHEP

Ipc: A61K 31/382 20060101ALI20070919BHEP

Ipc: A61P 27/10 20060101ALI20070919BHEP

Ipc: A61K 31/135 20060101AFI20070919BHEP

Ipc: A61K 31/37 20060101ALI20070919BHEP

Ipc: A61K 31/47 20060101ALI20070919BHEP

Ipc: A61K 31/495 20060101ALI20070919BHEP

Ipc: A61K 31/325 20060101ALI20070919BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070928

17Q First examination report despatched

Effective date: 20081121

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090402